After serving as Gilead’s chief medical officer for just six months, Andrew Cheng, M.D., Ph.D., has taken the top spot at Akero Therapeutics, not long after the biotech raised $65 million to move its lead nonalcoholic steatohepatitis candidate into phase 2 trials in the middle of next year.
And with the new president and CEO, Akero will relocate its headquarters from Cambridge, Massachusetts, to San Francisco, where Cheng is based. The company’s former CEO and co-founder, Jonathan Young, J.D., Ph.D., will stay on as executive VP and chief operating officer.
“Andrew’s appointment as president and CEO builds on the incredible momentum at Akero this past year,” Aaron Kantoff, Akero board member and principal at Apple Tree Partners, which helped lead June’s series A round, said in a release. “The ability of the company to attract someone of Andrew’s caliber is a testament to the groundwork laid by the founding team.”
Cheng first joined Gilead in 1999 and helped lead clinical development of its HIV/AIDS programs, as well as its development operations in oncology, inflammatory, respiratory and cardiovascular indications, and liver diseases.
Akero’s lead NASH program, AKR-001, is a long-acting fibroblast growth factor 21 analog—which plays a role in regulating metabolism and signaling in multiple organ systems—and has been previously evaluated in phase 1 studies of diabetic patients.
AKR-001 targets downstream NASH symptoms alongside the underlying cause of the disease, Akero said, by aiming to reduce liver fat while suppressing inflammation and fibrosis. The company plans to study AKR-001 in other metabolic diseases as well.
The sudden loss of Cheng at Gilead last month followed several exits from its C-suite. In April, Norbert Bischofberger, Ph.D., departed as chief scientific officer to launch his own drug discovery startup, Kronos Bio. In July, John Milligan, Ph.D., announced he would step down as CEO at year’s end after nearly three decades at the company, while Chairman John Martin, Ph.D., said he would step down after a new CEO is named.
By Conor Hale
Source: Fierce Biotech
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.